ContraVir Pharmaceuticals (CTRV) Given a $4.00 Price Target by Maxim Group Analysts

Maxim Group set a $4.00 price objective on ContraVir Pharmaceuticals (NASDAQ:CTRV) in a research note published on Monday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Separately, ValuEngine upgraded shares of ContraVir Pharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, February 2nd.

Shares of ContraVir Pharmaceuticals (NASDAQ CTRV) opened at $0.29 on Monday. ContraVir Pharmaceuticals has a 1 year low of $0.23 and a 1 year high of $1.96.

An institutional investor recently raised its position in ContraVir Pharmaceuticals stock. Vanguard Group Inc. increased its stake in shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,414,475 shares of the biopharmaceutical company’s stock after acquiring an additional 366,192 shares during the quarter. Vanguard Group Inc. owned about 3.79% of ContraVir Pharmaceuticals worth $1,400,000 at the end of the most recent quarter. 6.71% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/13/contravir-pharmaceuticals-ctrv-given-a-4-00-price-target-by-maxim-group-analysts.html.

ContraVir Pharmaceuticals Company Profile

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply